Notice: This company has been marked as potentially delisted and may not be actively trading. TF Financial (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends THRD vs. KROS, BLTE, GERN, LBPH, LGND, NAMS, AMPH, AKRO, MIRM, and SUPNShould you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Keros Therapeutics (KROS), Belite Bio (BLTE), Geron (GERN), Longboard Pharmaceuticals (LBPH), Ligand Pharmaceuticals (LGND), NewAmsterdam Pharma (NAMS), Amphastar Pharmaceuticals (AMPH), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceutical preparations" industry. TF Financial vs. Keros Therapeutics Belite Bio Geron Longboard Pharmaceuticals Ligand Pharmaceuticals NewAmsterdam Pharma Amphastar Pharmaceuticals Akero Therapeutics Mirum Pharmaceuticals Supernus Pharmaceuticals TF Financial (NASDAQ:THRD) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Is THRD or KROS more profitable? TF Financial has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. TF Financial's return on equity of -9.31% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TF FinancialN/A -9.31% -9.03% Keros Therapeutics -27,890.94%-41.74%-38.42% Does the media favor THRD or KROS? In the previous week, Keros Therapeutics had 21 more articles in the media than TF Financial. MarketBeat recorded 31 mentions for Keros Therapeutics and 10 mentions for TF Financial. Keros Therapeutics' average media sentiment score of 0.15 beat TF Financial's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TF Financial 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, THRD or KROS? TF Financial has higher earnings, but lower revenue than Keros Therapeutics. TF Financial is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTF FinancialN/AN/A-$30.82M-$0.62-22.97Keros Therapeutics$150K17,033.10-$152.99M-$5.21-12.11 Do institutionals & insiders believe in THRD or KROS? 94.0% of TF Financial shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 5.9% of TF Financial shares are owned by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate THRD or KROS? TF Financial presently has a consensus target price of $20.33, indicating a potential upside of 42.79%. Keros Therapeutics has a consensus target price of $88.89, indicating a potential upside of 40.94%. Given TF Financial's higher probable upside, equities research analysts clearly believe TF Financial is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TF Financial 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Keros Therapeutics 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, THRD or KROS? TF Financial has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Does the MarketBeat Community prefer THRD or KROS? TF Financial received 10 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 71.83% of users gave Keros Therapeutics an outperform vote while only 67.78% of users gave TF Financial an outperform vote. CompanyUnderperformOutperformTF FinancialOutperform Votes6167.78% Underperform Votes2932.22% Keros TherapeuticsOutperform Votes5171.83% Underperform Votes2028.17% SummaryTF Financial beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get TF Financial News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricTF FinancialPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$641.65M$6.77B$5.21B$8.94BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-22.9710.76133.9017.28Price / SalesN/A393.131,274.4091.64Price / CashN/A49.2238.8936.42Price / Book2.189.286.395.98Net Income-$30.82M$154.14M$118.47M$225.08M TF Financial Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDTF Financial1.1703 of 5 stars$12.90-9.4%$20.33+57.6%+136.9%$581.27MN/A-20.81N/AKROSKeros Therapeutics3.6849 of 5 stars$63.07-2.8%N/A+110.3%$2.55B$150,000.00-12.11100Analyst RevisionBLTEBelite Bio1.3603 of 5 stars$82.23+1.3%N/A+109.2%$2.52BN/A-74.0820Earnings ReportAnalyst ForecastShort Interest ↓GERNGeron3.537 of 5 stars$3.90+0.8%N/A+115.0%$2.36B$240,000.00-12.19141Earnings ReportAnalyst RevisionLBPHLongboard Pharmaceuticals1.4702 of 5 stars$59.78+0.1%N/A+1,112.6%$2.33BN/A-26.8120Earnings ReportShort Interest ↓LGNDLigand Pharmaceuticals4.9587 of 5 stars$122.08+1.1%N/A+121.3%$2.31B$131.31M48.6480Analyst ForecastGap DownNAMSNewAmsterdam Pharma3.2197 of 5 stars$24.60-0.6%N/A+164.5%$2.21B$14.09M0.0057Short Interest ↑Analyst RevisionAMPHAmphastar Pharmaceuticals4.8267 of 5 stars$45.48-4.7%N/A-15.1%$2.19B$644.40M15.161,761Insider SellingAKROAkero Therapeutics4.0283 of 5 stars$30.97-4.4%N/A+118.1%$2.16BN/A-8.2630Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageMIRMMirum Pharmaceuticals3.9281 of 5 stars$43.92+3.9%N/A+44.0%$2.10B$186.37M-21.74140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSUPNSupernus Pharmaceuticals2.4025 of 5 stars$37.77-0.2%N/A+38.2%$2.09B$607.52M35.30580 Related Companies and Tools Related Companies Keros Therapeutics Competitors Belite Bio Competitors Geron Competitors Longboard Pharmaceuticals Competitors Ligand Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Amphastar Pharmaceuticals Competitors Akero Therapeutics Competitors Mirum Pharmaceuticals Competitors Supernus Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THRD) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TF Financial Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share TF Financial With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THRD Stock Alerts